Max Rosett - Oct 2, 2023 Form 3 Insider Report for Immunome Inc. (IMNM)

Role
SVP Operations
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Stock symbol
IMNM
Transactions as of
Oct 2, 2023
Transactions value $
$0
Form type
3
Date filed
10/12/2023, 06:36 PM
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
holding IMNM Common Stock 19.9K Oct 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMNM Stock Option (Right to Buy) Oct 2, 2023 Common Stock 39.7K $1.35 Direct F2
holding IMNM Stock Option (Right to Buy) Oct 2, 2023 Common Stock 134K $1.06 Direct F2

Explanation of Responses:

Id Content
F1 Mr. Rosett was appointed as SVP Operations of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Mr. Rosett being appointed an executive officer of the Issuer, Mr. Rosett exchanged (i) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer and (ii) his shares of common stock of Morphimmune for shares of the Issuer.
F2 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.

Remarks:

See Attached Exhibit 24